ATNM · Actinium Pharmaceuticals Inc
United States · RS rating 30 · As of 2026-10-14
| Price | 0.97 USD |
|---|---|
| 1-day change | -2.5% |
| RS rating (overall / 1M / 3M / 12M) | 30 / 10 / 85 / 18 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 16 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +594.4% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +42.3% |
| Market cap (USD) | $41.1M |